Subclinical hyperthyroidism and the risk of coronary heart disease and mortality
- PMID: 22529182
- PMCID: PMC3872478
- DOI: 10.1001/archinternmed.2012.402
Subclinical hyperthyroidism and the risk of coronary heart disease and mortality
Abstract
Background: Data from prospective cohort studies regarding the association between subclinical hyperthyroidism and cardiovascular outcomes are conflicting.We aimed to assess the risks of total and coronary heart disease (CHD) mortality, CHD events, and atrial fibrillation (AF) associated with endogenous subclinical hyperthyroidism among all available large prospective cohorts.
Methods: Individual data on 52 674 participants were pooled from 10 cohorts. Coronary heart disease events were analyzed in 22 437 participants from 6 cohorts with available data, and incident AF was analyzed in 8711 participants from 5 cohorts. Euthyroidism was defined as thyrotropin level between 0.45 and 4.49 mIU/L and endogenous subclinical hyperthyroidism as thyrotropin level lower than 0.45 mIU/L with normal free thyroxine levels, after excluding those receiving thyroid-altering medications.
Results: Of 52 674 participants, 2188 (4.2%) had subclinical hyperthyroidism. During follow-up, 8527 participants died (including 1896 from CHD), 3653 of 22 437 had CHD events, and 785 of 8711 developed AF. In age- and sex-adjusted analyses, subclinical hyperthyroidism was associated with increased total mortality (hazard ratio[HR], 1.24, 95% CI, 1.06-1.46), CHD mortality (HR,1.29; 95% CI, 1.02-1.62), CHD events (HR, 1.21; 95%CI, 0.99-1.46), and AF (HR, 1.68; 95% CI, 1.16-2.43).Risks did not differ significantly by age, sex, or preexisting cardiovascular disease and were similar after further adjustment for cardiovascular risk factors, with attributable risk of 14.5% for total mortality to 41.5% forAF in those with subclinical hyperthyroidism. Risks for CHD mortality and AF (but not other outcomes) were higher for thyrotropin level lower than 0.10 mIU/L compared with thyrotropin level between 0.10 and 0.44 mIU/L(for both, P value for trend, .03).
Conclusion: Endogenous subclinical hyperthyroidism is associated with increased risks of total, CHD mortality, and incident AF, with highest risks of CHD mortality and AF when thyrotropin level is lower than 0.10 mIU/L.
Figures
Comment in
-
What is the clinical importance of subclinical hyperthyroidism?Arch Intern Med. 2012 May 28;172(10):809-10. doi: 10.1001/archinternmed.2012.1114. Arch Intern Med. 2012. PMID: 22529181 No abstract available.
Similar articles
-
Subclinical hypothyroidism and the risk of coronary heart disease and mortality.JAMA. 2010 Sep 22;304(12):1365-74. doi: 10.1001/jama.2010.1361. JAMA. 2010. PMID: 20858880 Free PMC article.
-
Thyroid Function Within the Normal Range, Subclinical Hypothyroidism, and the Risk of Atrial Fibrillation.Circulation. 2017 Nov 28;136(22):2100-2116. doi: 10.1161/CIRCULATIONAHA.117.028753. Epub 2017 Oct 23. Circulation. 2017. PMID: 29061566 Free PMC article. Review.
-
Subclinical thyroid dysfunction and fracture risk: a meta-analysis.JAMA. 2015 May 26;313(20):2055-65. doi: 10.1001/jama.2015.5161. JAMA. 2015. PMID: 26010634 Free PMC article.
-
Thyroid status, cardiovascular risk, and mortality in older adults.JAMA. 2006 Mar 1;295(9):1033-41. doi: 10.1001/jama.295.9.1033. JAMA. 2006. PMID: 16507804 Free PMC article.
-
[Subclinical hyperthyroidism].Dtsch Med Wochenschr. 2013 Oct;138(42):2146-50. doi: 10.1055/s-0033-1343278. Epub 2013 Jul 19. Dtsch Med Wochenschr. 2013. PMID: 23873176 Review. German.
Cited by
-
Evaluation of the risk of hypothyroidism and its clinical manifestations using the Zulewski scale.Front Endocrinol (Lausanne). 2024 Aug 16;15:1416663. doi: 10.3389/fendo.2024.1416663. eCollection 2024. Front Endocrinol (Lausanne). 2024. PMID: 39220359 Free PMC article.
-
Impact of thyroid function on coagulation and venous thromboembolism: a two-sample mendelian randomization study.J Thromb Thrombolysis. 2024 Oct;57(7):1145-1153. doi: 10.1007/s11239-024-03025-7. Epub 2024 Aug 7. J Thromb Thrombolysis. 2024. PMID: 39110374
-
Daily exposure to low concentrations Tetrabromobisphenol A interferes with the thyroid hormone pathway in HepG2 cells.Fundam Res. 2023 Jan 30;3(3):384-391. doi: 10.1016/j.fmre.2022.03.019. eCollection 2023 May. Fundam Res. 2023. PMID: 38933766 Free PMC article.
-
A systematic review of subclinical hyperthyroidism guidelines: a remarkable range of recommendations.Eur Thyroid J. 2024 Jun 13;13(3):e240036. doi: 10.1530/ETJ-24-0036. Print 2024 Jun 1. Eur Thyroid J. 2024. PMID: 38758966 Free PMC article.
-
Epidemiology, prognosis, and challenges in the management of hyperthyroidism-related atrial fibrillation.Eur Thyroid J. 2024 Apr 1;13(2):e230254. doi: 10.1530/ETJ-23-0254. Print 2024 Apr 1. Eur Thyroid J. 2024. PMID: 38377675 Free PMC article. Review.
References
-
- Surks MI, Ortiz E, Daniels GH, et al. Subclinical thyroid disease: scientific review and guidelines for diagnosis and management. JAMA. 2004;291(2):228–238. - PubMed
-
- Gharib H, Tuttle RM, Baskin HJ, Fish LH, Singer PA, McDermott MT. Subclinical thyroid dysfunction: a joint statement on management from the American Association of Clinical Endocrinologists, the American Thyroid Association, and the Endocrine Society. J Clin Endocrinol Metab. 2005;90(1):581–587. - PubMed
-
- Biondi B, Cooper DS. The clinical significance of subclinical thyroid dysfunction. Endocr Rev. 2008;29(1):76–131. - PubMed
-
- Bahn RS, Burch HB, Cooper DS, et al. American Thyroid Association; American Association of Clinical Endocrinologists. Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists. Thyroid. 2011;21(6):593–646. - PubMed
-
- Biondi B. Endogenous subclinical hyperthyroidism: who, when and why to treat. Expert Rev Endocrinol Metab. 2011;6(6):785–792. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- R01 HL075366/HL/NHLBI NIH HHS/United States
- K24 AR051895/AR/NIAMS NIH HHS/United States
- R01-NR012459/NR/NINR NIH HHS/United States
- N01HC55222/HL/NHLBI NIH HHS/United States
- AG-027058/AG/NIA NIH HHS/United States
- N01-HC-85082/HC/NHLBI NIH HHS/United States
- N01 HC-55222/HC/NHLBI NIH HHS/United States
- R01 AG028050/AG/NIA NIH HHS/United States
- N01-HC-85079/HC/NHLBI NIH HHS/United States
- N01-AG-62103/AG/NIA NIH HHS/United States
- R01 AG027058/AG/NIA NIH HHS/United States
- R56 AG023629/AG/NIA NIH HHS/United States
- P30 AG024827/AG/NIA NIH HHS/United States
- R01 AG-15928/AG/NIA NIH HHS/United States
- N01-HC-80007/HC/NHLBI NIH HHS/United States
- N01-HC-85085/HC/NHLBI NIH HHS/United States
- R01 AG015928/AG/NIA NIH HHS/United States
- U01 HL080295/HL/NHLBI NIH HHS/United States
- N01-HC-85081/HC/NHLBI NIH HHS/United States
- N01-AG-62101/AG/NIA NIH HHS/United States
- P30-AG-024827/AG/NIA NIH HHS/United States
- AG-032317/AG/NIA NIH HHS/United States
- N01-HC-85086/HC/NHLBI NIH HHS/United States
- R01 NR012459/NR/NINR NIH HHS/United States
- N01HC85086/HL/NHLBI NIH HHS/United States
- G0401527/MRC_/Medical Research Council/United Kingdom
- N01-AG-62106/AG/NIA NIH HHS/United States
- N01-HC-85083/HC/NHLBI NIH HHS/United States
- N01 HC-75150/HC/NHLBI NIH HHS/United States
- N01-HC-85080/HC/NHLBI NIH HHS/United States
- G1000143/MRC_/Medical Research Council/United Kingdom
- R01 AG-20098/AG/NIA NIH HHS/United States
- R01 AG020098/AG/NIA NIH HHS/United States
- R01 AG032317/AG/NIA NIH HHS/United States
- N01HC75150/HL/NHLBI NIH HHS/United States
- AG-023629/AG/NIA NIH HHS/United States
- N01HC85079/HL/NHLBI NIH HHS/United States
- R01 AG023629/AG/NIA NIH HHS/United States
- CRUK_/Cancer Research UK/United Kingdom
- N01-HC-85084/HC/NHLBI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Medical
